How has Prime Medicine's accrued expenses and other liabilities changed year-over-year?

Prime Medicine's accrued expenses and other liabilities increased by 32.4% year-over-year, from -$6.66M to -$4.5M.

Prime Medicine PRME Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Vertex PharmaceuticalsVRTX

——

Beam TherapeuticsBEAM

——

RegenxbioRGNX

——

Sarepta Therapeutics, Inc.SRPT

——

Sana BiotechnologySANA

——

PVL

Palvella TherapeuticsPVLA

——

Other financials

Income statement

See full

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

See full

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

See full

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

See full

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

See full

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

See full

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Prime Medicine's accrued expenses and other liabilities?: Prime Medicine (PRME) reported accrued expenses and other liabilities of -$4.5M in Q1 2026.
How has Prime Medicine's accrued expenses and other liabilities changed year-over-year?: Prime Medicine's accrued expenses and other liabilities increased by 32.4% year-over-year, from -$6.66M to -$4.5M.